Jeremy Puthumana, MD, MS
Clinical AssociateAbout
Research
Publications
Featured Publications
Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration
Puthumana J, Egilman AC, Zhang AD, Schwartz JL, Ross JS. Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration. JAMA Internal Medicine 2021, 181: 559-560. PMID: 33170923, PMCID: PMC7656319, DOI: 10.1001/jamainternmed.2020.7472.Peer-Reviewed Original ResearchBiomarkers of inflammation and repair in kidney disease progression
Puthumana J, Thiessen-Philbrook H, Xu L, Coca SG, Garg AX, Himmelfarb J, Bhatraju PK, Ikizler T, Siew E, Ware LB, Liu KD, Go AS, Kaufman JS, Kimmel PL, Chinchilli VM, Cantley L, Parikh CR. Biomarkers of inflammation and repair in kidney disease progression. Journal Of Clinical Investigation 2021, 131 PMID: 33290282, PMCID: PMC7843225, DOI: 10.1172/jci139927.Peer-Reviewed Original ResearchConceptsKidney disease progressionComposite kidney outcomeChronic kidney diseaseDisease progressionEGFR declineKidney outcomesRenal atrophyMouse modelMonocyte chemoattractant protein-1CHI3L1 mRNA expressionComposite renal outcomeGreater eGFR declineIntroductionAcute kidney injuryProspective cohort studyGlomerular filtration rateBiomarkers of inflammationProgressive renal fibrosisYKL-40 levelsChemoattractant protein-1Traditional clinical variablesLong-term progressionLoop of HenleMultimarker scoreRenal outcomesKidney injuryClinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation
Puthumana J, Wallach JD, Ross JS. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation. JAMA: The Journal Of The American Medical Association 2018, 320: 301-303. PMID: 30027239, PMCID: PMC6583484, DOI: 10.1001/jama.2018.7619.Peer-Reviewed Original ResearchUrine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis
Puthumana J, Ariza X, Belcher JM, Graupera I, Ginès P, Parikh CR. Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology And Hepatology 2016, 15: 1003-1013.e3. PMID: 28013112, PMCID: PMC5474196, DOI: 10.1016/j.cgh.2016.11.035.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNeutrophil Gelatinase-Associated LipocalinAcute tubular necrosisUrine levelsUrine biomarkersSystematic reviewKidney impairmentKidney injuryTubular necrosisLipocalin-2Development of ATNAUC valuesEtiology of AKIUrine interleukin-18Acute kidney injuryGelatinase-Associated LipocalinShort-term mortalityLogistic mixed-effects modelsHepatorenal syndromeCause mortalityPrerenal azotemiaCommon complicationInterleukin-18Prospective studyPatient outcomesCommon cause